Anaplastic Oligoastrocytoma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Anaplastic Oligoastrocytoma - Pipeline Review, H1 2016', provides an overview of the Anaplastic Oligoastrocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma - The report reviews pipeline therapeutics for Anaplastic Oligoastrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Anaplastic Oligoastrocytoma therapeutics and enlists all their major and minor projects - The report assesses Anaplastic Oligoastrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Anaplastic Oligoastrocytoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anaplastic Oligoastrocytoma Overview 6 Therapeutics Development 7 Pipeline Products for Anaplastic Oligoastrocytoma - Overview 7 Pipeline Products for Anaplastic Oligoastrocytoma - Comparative Analysis 8 Anaplastic Oligoastrocytoma - Therapeutics under Development by Companies 9 Anaplastic Oligoastrocytoma - Therapeutics under Investigation by Universities/Institutes 10 Anaplastic Oligoastrocytoma - Pipeline Products Glance 11 Clinical Stage Products 11 Anaplastic Oligoastrocytoma - Products under Development by Companies 12 Anaplastic Oligoastrocytoma - Products under Investigation by Universities/Institutes 13 Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development 14 Axelar AB 14 Cavion LLC 15 Celldex Therapeutics, Inc. 16 e-Therapeutics Plc 17 Novartis AG 18 Pfizer Inc. 19 Anaplastic Oligoastrocytoma - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 AXL-1717 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CDX-1401 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Cellular Immunotherapy for Brain Tumors - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Cellular Immunotherapy for Gliomas - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ETS-2101 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 flucytosine + TBio-01 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 mibefradil dihydrochloride - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 nilotinib - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 palbociclib - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Anaplastic Oligoastrocytoma - Recent Pipeline Updates 51 Anaplastic Oligoastrocytoma - Dormant Projects 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Anaplastic Oligoastrocytoma, H1 2016 7 Number of Products under Development for Anaplastic Oligoastrocytoma - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Anaplastic Oligoastrocytoma - Pipeline by Axelar AB, H1 2016 14 Anaplastic Oligoastrocytoma - Pipeline by Cavion LLC, H1 2016 15 Anaplastic Oligoastrocytoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 16 Anaplastic Oligoastrocytoma - Pipeline by e-Therapeutics Plc, H1 2016 17 Anaplastic Oligoastrocytoma - Pipeline by Novartis AG, H1 2016 18 Anaplastic Oligoastrocytoma - Pipeline by Pfizer Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Assessment by Combination Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Anaplastic Oligoastrocytoma Therapeutics - Recent Pipeline Updates, H1 2016 51 Anaplastic Oligoastrocytoma - Dormant Projects, H1 2016 66
List of Figures
Number of Products under Development for Anaplastic Oligoastrocytoma, H1 2016 7 Number of Products under Development for Anaplastic Oligoastrocytoma - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Top 10 Targets, H1 2016 22 Number of Products by Stage and Top 10 Targets, H1 2016 22 Number of Products by Top 10 Mechanism of Actions, H1 2016 24 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 24 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Molecule Types, H1 2016 28 Number of Products by Stage and Molecule Types, H1 2016 28
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance drivRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.